Cost of care for individuals with cystic fibrosis: a regression approach to determining the impact of recombinant human DNase.
We estimated direct medical costs of care and important determinants of the costs in patients with cystic fibrosis (CF), including therapy with recombinant human DNase (rhDNase). Costs were estimated with resource use data from the Epidemiologic Study of Cystic Fibrosis. Ordinary least squares regression was used to determine the effect of clinical and demographic variables on individual cost of care. The estimated cost of caring for 303 patients in Alberta was $2,279,801 in 1996. The mean cost of care was $7524 (range $386-92,376)/patient. Regression results indicated that age and forced expiratory volume predicted had a negative association with costs. Being female, receiving rhDNase, and having Pseudomonas aeruginosa or Burkholderia cepacia were all associated with high costs. Our estimates indicated large interindividual variation in cost of care for patients with CF.
Johnson
J A
JA
Institute of Health Economics, Faculty of Pharmacy and Pharmaceutical Sciences, the University of Alberta, Edmonton, Canada.
Connolly
M A
MA
Jacobs
P
P
Montgomery
M
M
Brown
N E
NE
Zuberbuhler
P
P
D000328:Adult; D000367:Age Factors; D019121:Burkholderia Infections / Q000188:drug therapy / Q000191:economics*; D002648:Child; D002675:Child, Preschool; D003550:Cystic Fibrosis / Q000188:drug therapy* / Q000191:economics* / Q000235:genetics; D003625:Data Collection; D003851:Deoxyribonucleases / Q000627:therapeutic use*; D005260:Female; D005541:Forced Expiratory Volume / Q000187:drug effects; D006801:Humans; D008297:Male; D011552:Pseudomonas Infections / Q000188:drug therapy / Q000191:economics*; D011994:Recombinant Proteins / Q000627:therapeutic use; D012044:Regression Analysis
D011994:Recombinant Proteins; D003851:Deoxyribonucleases